ME01320B - Derivati citokina - Google Patents

Derivati citokina

Info

Publication number
ME01320B
ME01320B MEP-2011-47A MEP4711A ME01320B ME 01320 B ME01320 B ME 01320B ME P4711 A MEP4711 A ME P4711A ME 01320 B ME01320 B ME 01320B
Authority
ME
Montenegro
Prior art keywords
polypeptide
nucleic acid
diseases
host cell
indicated
Prior art date
Application number
MEP-2011-47A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Olivier Hartley
Original Assignee
The Mintaka Medical Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Mintaka Medical Res Foundation filed Critical The Mintaka Medical Res Foundation
Publication of ME01320B publication Critical patent/ME01320B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
MEP-2011-47A 2006-07-25 2007-07-25 Derivati citokina ME01320B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives
EP07825334A EP2076532B1 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
ME01320B true ME01320B (me) 2013-12-20

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2011-47A ME01320B (me) 2006-07-25 2007-07-25 Derivati citokina

Country Status (25)

Country Link
US (2) US8686111B2 (https=)
EP (1) EP2076532B1 (https=)
JP (1) JP5224603B2 (https=)
KR (1) KR101530353B1 (https=)
CN (1) CN101511867B (https=)
AT (1) ATE490270T1 (https=)
AU (1) AU2007278894B2 (https=)
BR (1) BRPI0715331B8 (https=)
CA (1) CA2658806C (https=)
CY (1) CY1111630T1 (https=)
DE (1) DE602007010969D1 (https=)
DK (1) DK2076532T3 (https=)
ES (1) ES2361455T3 (https=)
GB (1) GB0614755D0 (https=)
HR (1) HRP20110146T1 (https=)
ME (1) ME01320B (https=)
MX (1) MX2009000918A (https=)
NZ (1) NZ575092A (https=)
PL (1) PL2076532T3 (https=)
PT (1) PT2076532E (https=)
RS (1) RS51854B (https=)
RU (1) RU2461567C2 (https=)
SI (1) SI2076532T1 (https=)
WO (1) WO2008012689A2 (https=)
ZA (1) ZA200901342B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
CA3101556A1 (en) * 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Ccr5 inhibitor for use in treating cancer
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv-1肽类
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
DE602007010969D1 (de) 2011-01-13
GB0614755D0 (en) 2006-09-06
HK1131162A1 (en) 2010-01-15
EP2076532B1 (en) 2010-12-01
RU2461567C2 (ru) 2012-09-20
JP5224603B2 (ja) 2013-07-03
BRPI0715331B8 (pt) 2021-05-25
US20090317363A1 (en) 2009-12-24
US9328153B2 (en) 2016-05-03
ZA200901342B (en) 2010-11-24
NZ575092A (en) 2011-08-26
HRP20110146T1 (hr) 2011-06-30
DK2076532T3 (da) 2011-03-07
CA2658806C (en) 2017-01-03
KR20090060281A (ko) 2009-06-11
CN101511867B (zh) 2014-04-09
RS51854B (sr) 2012-02-29
BRPI0715331A2 (pt) 2013-07-16
CN101511867A (zh) 2009-08-19
SI2076532T1 (sl) 2011-06-30
PT2076532E (pt) 2011-03-02
PL2076532T3 (pl) 2011-07-29
WO2008012689A3 (en) 2008-05-08
ES2361455T3 (es) 2011-06-17
RU2009106436A (ru) 2010-08-27
JP2009544304A (ja) 2009-12-17
US8686111B2 (en) 2014-04-01
AU2007278894A1 (en) 2008-01-31
ATE490270T1 (de) 2010-12-15
CA2658806A1 (en) 2008-01-31
KR101530353B1 (ko) 2015-06-26
EP2076532A2 (en) 2009-07-08
BRPI0715331B1 (pt) 2021-04-13
MX2009000918A (es) 2009-08-26
CY1111630T1 (el) 2015-10-07
AU2007278894B2 (en) 2012-08-09
US20130330305A1 (en) 2013-12-12
WO2008012689A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
ME01320B (me) Derivati citokina
TW201406959A (zh) 抗發炎胜肽及包含其之成分(三)
HRP20110368T1 (hr) Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
CN105327350A (zh) 泛素化途径相关因子在调控辅助性t细胞功能中的应用
CN103030687B (zh) 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
JP2006506942A5 (https=)
US20140073555A1 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
JP2009544304A5 (https=)
MX2010006211A (es) Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.
JP2023517616A (ja) 急性呼吸窮迫症候群およびウイルス感染の治療用のcxcr4阻害剤
HRP20140888T1 (hr) Humana monoklonalna protutijela za humani il-4
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
JP2017519763A5 (https=)
Il’in et al. Analysis of IL-1α, bFGF, TGF-β1, IFNγ, MMP-1, and CatD expression in multinuclea macrophages in vitro
US8815812B2 (en) Synthetic arginine substituted peptides and their use
CN102115495B (zh) 胶原靶向治疗增生性瘢痕蛋白药物的制备及应用
JP2011503008A5 (https=)
CN102241748B (zh) D29分枝杆菌噬菌体来源的pk34多肽及其应用
JP2020519623A (ja) メトトレキサートとペプチドの結合体
CN101684159A (zh) 人颗粒酶b蛋白衍生物及其在靶向治疗腺癌中的用途
JP2017525357A5 (https=)
CN111788217A (zh) 白介素-15活性的拮抗剂肽
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
WO2021046626A3 (pt) Peptídeos anti-inflamatório, composição farmacêutica compreendendo tais peptídeos e seus usos